FIELD: biotechnology.
SUBSTANCE: following is presented: a monospecific binding protein that binds a CD38 polypeptide, a conjugate for targeting a cytotoxic agent or tag to cells expressing CD38 on their surface, a polynucleotide encoding a monospecific binding protein, an expression vector containing the polynucleotide and a host cell. A method of producing a monospecific binding protein is also disclosed.
EFFECT: obtaining new antibodies with high affinity for HLA-G.
18 cl, 40 dwg, 27 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
